GS-012 Efruxifermin improves fibrosis in participants with compensated cirrhosis due to MASH: results of a 96-week, randomized, doubleblind, placebo-controlled, phase 2b trial (SYMMETRY)

IF 33 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2025-05-01 DOI:10.1016/S0168-8278(25)00309-5

Mazen Noureddin, Mary E. Rinella, Naga Chalasani, Guy Neff, Kathryn Lucas, Manuel Rodriguez, Madhavi Rudraraju, Rashmee Patil, Cynthia Behling, Mark Burch, Doreen Chan, Erik Tillman, Arian Zari, Brittany de Temple, Reshma Shringarpure, Meena Jain, Tim Rolph, Andrew Cheng, Kitty Yale

引用次数: 0

查看原文本刊更多论文

GS-012 Efruxifermin改善MASH代偿性肝硬化患者的纤维化：一项为期96周、随机、双盲、安慰剂对照的2b期试验结果（SYMMETRY）

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.